ArticleHaematologica2015
Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype.
Open access · goldAbstract readEvaluation StudyLetter
In one paragraph
Article in Haematologica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Impact of mutations in epigenetic modifiers in acute myeloid leukemia: A systematic review and meta-analysis.Frontiers in oncology · 2022Pooled it
- The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis.BMC cancer · 2019Pooled it
- Prognostic implications ofBlood neoplasia · 2026Article
- Article
- Landscape of TET2 Mutations: From Hematological Malignancies to Solid Tumors.Cancer medicine · 2025Review
- TET2 mutation in acute myeloid leukemia: biology, clinical significance, and therapeutic insights.Clinical epigenetics · 2024Review
- Synthetic lethal targeting of TET2-mutant haematopoietic stem and progenitor cells by XPO1 inhibitors.British journal of haematology · 2023Article
- Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies.Signal transduction and targeted therapy · 2023Review
- Biallelic TET2 mutations confer sensitivity to 5'-azacitidine in acute myeloid leukemia.JCI insight · 2023Article
- Role of TET dioxygenases in the regulation of both normal and pathological hematopoiesis.Journal of experimental & clinical cancer research : CR · 2022Review
- TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy.Current issues in molecular biology · 2021Article
- Role of Tet2 in Regulating Adaptive and Innate Immunity.Frontiers in cell and developmental biology · 2021Review
- A systematic literature review of disease burden and clinical efficacy for patients with relapsed or refractory acute myeloid leukemia.American journal of blood research · 2021Review
- Article
- Landscape of Tumor Suppressor Mutations in Acute Myeloid Leukemia.Journal of clinical medicine · 2020Review
- Acidic leucine-rich nuclear phosphoprotein-32A expression contributes to adverse outcome in acute myeloid leukemia.Annals of translational medicine · 2020Article
- Ten-eleven translocation-2 affects the fate of cells and has therapeutic potential in digestive tumors.Chronic diseases and translational medicine · 2019Article
- Genome-Wide Analysis of Head and Neck Squamous Cell Carcinomas Reveals HPV, TP53, Smoking and Alcohol-Related Allele-Based Acquired Uniparental Disomy Genomic Alterations.Neoplasia (New York, N.Y.) · 2019Article
- TET2 Function in Hematopoietic Malignancies, Immune Regulation, and DNA Repair.Frontiers in oncology · 2019Review
- Donor lymphocyte infusion for prevention of relapse after unmanipulated haploidentical PBSCT for very high-risk hematologic malignancies.Annals of hematology · 2019Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 8 institutions in 3 countries.
Jae-Sook AhnHematology-Oncology, Chonnam National University Hwasun Hospital, Jeollanam-do, Republic of Korea.
Hyeoung-Joon KimHematology-Oncology, Chonnam National University Hwasun Hospital, Jeollanam-do, Republic of Korea hjoonk@chonnam.ac.kr.
Yeo-Kyeoung KimHematology-Oncology, Chonnam National University Hwasun Hospital, Jeollanam-do, Republic of Korea.
Sung-Hoon JungHematology-Oncology, Chonnam National University Hwasun Hospital, Jeollanam-do, Republic of Korea.
Deok-Hwan YangHematology-Oncology, Chonnam National University Hwasun Hospital, Jeollanam-do, Republic of Korea.
Je-Jung LeeHematology-Oncology, Chonnam National University Hwasun Hospital, Jeollanam-do, Republic of Korea.
Il-Kwon LeeGenomic Research Center for Hematopoietic Diseases, Chonnam National University Hwasun Hospital, Jeollanam-do, Republic of Korea.
Nan Young KimGenomic Research Center for Hematopoietic Diseases, Chonnam National University Hwasun Hospital, Jeollanam-do, Republic of Korea.
Mark D MindenDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Canada.
Chul Won JungDivision of Hematology-Oncology, Samsung Medical Center, Seoul, Republic of Korea.
Jun-Ho JangDivision of Hematology-Oncology, Samsung Medical Center, Seoul, Republic of Korea.
Hee Je KimDepartment of Hematology, The Catholic University of Korea, Seoul, Republic of Korea.
Joon Ho MoonDepartment of Hematology-Oncology, Kyungpook National University Hospital, Daegu, Republic of Korea.
Sang Kyun SohnDepartment of Hematology-Oncology, Kyungpook National University Hospital, Daegu, Republic of Korea.
Jong-Ho WonDepartment of Hematology-Oncology, Soon Chun Hyang University Hospital, Seoul, Republic of Korea.
Sung-Hyun KimDepartment of Hematology-Oncology, Dong-A University College of Medicine, Busan, Republic of Korea.
Namshin KimEpigenomics Research Center, Genome Institute, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.
Kenichi YoshidaKyoto University, Japan.
Seishi OgawaKyoto University, Japan.
Dennis Dong Hwan KimDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Canada.
Chonnam National University Hwasun Hospital · KRCatholic University of Korea · KRKorea Research Institute of Bioscience and Biotechnology · KRKyoto University · JPKyungpook National University Hospital · KRPrincess Margaret Cancer Centre · CASamsung Medical Center · KRSoonchunhyang University Hospital Seoul · KR
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
HomozygoteKaryotypeLeukemia, Myeloid, AcuteMutationAdolescentAdultDioxygenasesDisease-Free SurvivalDNA-Binding ProteinsFemaleFollow-Up StudiesHumansMaleMiddle AgedProto-Oncogene ProteinsSurvival RateDioxygenasesDNA-Binding ProteinsProto-Oncogene ProteinsTET2 protein, humanacute myeloid leukemiahomozygous mutationnormal karyotypeTET2
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.